Flt3 Ligand, Recombinant, Mouse (Fms-like Tyrosine Kinase 3 Ligand, flk2 Ligand)

Human FLT3 ligand also stimulates the proliferation of cells expressing murine FLT-3 receptors. The effects of FLT-3 ligand are synergized by coexpression of G-CSF , GM-CSF , M-CSF , IL3 and SCF . FLT-3 ligand promotes long-term expansion and differentiation of human pro-B-cells in the presence of IL7 or in combination of IL7 and IL3 . \n\nRecombinant Murine Flt3-Ligand is a non-glycosylated, polypeptide chain containing 144 amino acids with a MW of 16.43kD. \n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Thr-Gln-Asp-Cys-Ser. \n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis. \n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC, using a standard solution of FLT3 as a Reference Standard. \n\nBiological Activity:\nrmFlt3-Ligand is fully biologically active when compared to standard. The activity is determined by the ability to generate CD11c+ splenic dendritic cells in vivo in C57B1/6-12 week female mice. To obtain the desired affect, mice were treated with approximately 25ug of flt3-ligand once daily for 9 consecutive days via intraperitoneal injection.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. For long-term storage, store below -20 degrees C. Reconstitute to nominal volume by adding sterile ddH2O, 0.1% HSA or BSA and store below -20 degrees C. Reconstituted product is stable for 12 months below -20 degrees C. Avoid freeze-thaw cycles. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

F4600-15

Size

2ug

Form

Supplied as a white lyophilized powder with no additives. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml

Purity

(same/more than) 98% by RP-HPLC, anion-exchange FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Endotoxin: (same/less than) 0.1ng/ug (1EU/ug)

References

1. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. Ciavarra RP, Holterman DA, Mangiotti P, Glass WF, J Immunother 2004 Jan-Feb;27(1):13-26 2. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Ciavarra RP, Brown RR, Garrett M, Somers KD, Cancer Immunol Immunother 2003 Sep;52(9):535-45 3. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Somers KD, Brown RR, Yousefieh N, Qian J, Int J Cancer 2003 Dec 10;107(5):773-80 4. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Ciavarra RP, Brown RR, Garrett M, Somers KD, Cancer Immunol Immunother 2003 Jun 24; 5. Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model. Agrawal DK, Hopfenspirger MT, Talmadge JE, Int Immunopharmacol 2001 Nov;1(12):2081-9 6. Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses. Li W, Lu L, Wang Z, Transplant Proc 2001 Feb-Mar;33(1-2):525.